Gonadorelin (GnRH): Clinical Overview for Providers

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), also called LHRH and historically marketed as Factrel. It sits at the top of the reproductive endocrine axis. Its defining pharmacologic property is one every clinician prescribing in this space should understand: its effect depends entirely on the pattern of administration, not merely the dose.

This guide situates Gonadorelin within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What is gonadorelin?

Gonadorelin is a decapeptide identical to endogenous GnRH. It is produced in the hypothalamus and released into the portal circulation reaching the anterior pituitary, where it stimulates gonadotroph cells to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Those gonadotropins then act on the gonads: LH drives testosterone production by Leydig cells in men and ovulation in women, while FSH supports spermatogenesis and follicular development.

Its plasma half-life is only a few minutes, which is a central practical constraint on how it can be used.

Why timing reverses the effect

Endogenous GnRH is released in discrete pulses, roughly every 60 to 120 minutes in men, with frequency varying across the menstrual cycle in women. The pituitary gonadotroph is built to respond to that pattern.

Deliver GnRH in a pulsatile fashion and the axis is stimulated: LH and FSH rise, and downstream gonadal function follows. This is the basis for pulsatile GnRH pump therapy in hypogonadotropic hypogonadism, where it can restore fertility.

Deliver the same molecule continuously and the effect inverts. Sustained receptor occupancy causes gonadotroph GnRH receptors to downregulate and desensitize. After a brief initial flare, LH and FSH fall and the axis is suppressed. This is precisely how GnRH agonists are used to induce medical castration in prostate cancer and to suppress the axis in endometriosis and precocious puberty.

The same molecule, opposite outcomes, determined by timing. This is the single most important fact about gonadorelin, and it is why casual dosing schedules copied from the internet are not a trivial matter.

Use alongside testosterone therapy

Gonadorelin has become widely discussed in men receiving testosterone replacement therapy. Exogenous testosterone suppresses LH and FSH through negative feedback, which leads to testicular atrophy and impaired spermatogenesis. The rationale for adding a GnRH stimulus is to maintain testicular function during therapy.

Two honest caveats belong with that rationale. First, the very short half-life makes achieving a genuinely pulsatile stimulus difficult with ordinary injection schedules — and if the pattern drifts toward sustained exposure, the pharmacology described above predicts suppression rather than support. Second, hCG has historically been the better-established agent for this purpose, acting directly at the LH receptor on Leydig cells and bypassing the pituitary entirely.

This use is off-label, the comparative evidence base is thinner than the confidence with which it is discussed online, and it belongs in a considered clinical conversation rather than a protocol copied from a forum.

Regulatory status and sourcing

Gonadorelin's availability in the United States has changed over time, and its compounding status falls into the category requiring direct verification rather than assumption. Our peptide formulary carries a current status tag.

Material sold online under this name is an unregulated research chemical. Given a molecule whose therapeutic and suppressive effects are separated only by administration pattern, uncertainty about concentration is a more consequential problem than it first appears.